Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 362-368

  Sharma, Neelesh ^a,d   Pennell, Nathan ^a   Nickolich, Myles ^c   Halmos, Balazs ^b   Ma, Patrick ^a   Mekhail, Tarek ^a   Fu, Pingfu ^c   Dowlati, Afshin ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Angiogenesis inhibitor; Small cell lung cancer; Sorafenib; VEGFR tyrosine kinase inhibitor

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; LUNG HEMORRHAGE; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VERY ELDERLY; WEIGHT REDUCTION; YOUNG ADULT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84896396890     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0061-6     Document Type: Article

References (32)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236
2. Seifter EJ, Ihde DC (1988) Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 15:278-299
3. Hanna N, Bunn PA Jr, Langer C et al (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038-2043
4. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122
5. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544
6. Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12:567-580
7. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA (2002) Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21:1105-1110
8. Ruotsalainen T, Joensuu H, Mattson K, Salven P (2002) High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 11:1492-1495
9. Salven P, Ruotsalainen T, Mattson K, Joensuu H (1998) High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79:144-146
10. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
11. Zhang J, Gold KA, Kim E (2012) Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs 21:1417-1426
12. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
13. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
14. Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW (2004) The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46:283-291
15. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-488
16. Ibrahim N, Yu Y, Walsh WR, Yang JL (2012) Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep 27:1303-1311
17. Gitlitz BJ, Moon J, Glisson BS et al (2010) Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 5:1835-1840
18. Ready N, Dunphy F, Pang H et al (2010) Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. J Clin Oncol 28:15s (suppl, abstract 7056)
19. Ramalingam SS, Belani CP, Mack PC et al (2010) Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 5:1279-1284
20. Arnold AM, Seymour L, Smylie M et al (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25:4278-4284
21. Schneider BJ, Gadgeel SM, Ramnath N et al (2011) Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 6:1117-1120
22. Spigel DR, Greco FA, Rubin MS et al (2012) Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer 7:359-364
23. Horn L, Dahlberg SE, Sandler AB et al (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-6011
24. Ready NE, Dudek AZ, Pang HH et al (2011) Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 29:4436-4441
25. Spigel DR, Greco FA, Zubkus JD et al (2009) Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 4:1555-1560
26. Spigel DR, Townley PM, Waterhouse DM et al (2011) Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 29:2215-2222
27. Goss GD, Arnold A, Shepherd FA et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55
28. Baselga J, Segalla JG, Roche H et al (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30:1484-1491
29. Kim ES, Herbst RS, Wistuba II et al (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1:44-53
30. Mok TS, Paz-Ares L, Wu YL et al (2012) Association between tumor EGFR and KRAS mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the phase III MISSION trial. Ann Oncol 23:9s (suppl, abstract LBA9-PR)
31. Waterhouse DM, Morgan SK, Spigel DR et al (2010) Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer. J Clin Oncol 28:15s (suppl, abstract 7055)
32. Allen JW, Moon J, Gadgeel SM et al (2012) SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC). J Clin Oncol 30:15s (suppl, abstract 7005)